Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,359.99 +13.00 (+0.24%) Dow
38,865.56 +66.57 (+0.17%) Nasdaq
17,181.52 +48.40 (+0.28%) Bitcoin USD
69,840.83 +116.48 (+0.17%) CMC Crypto 200
1,448.77 +2.10 (+0.15%)
HROW Jun 2024 18.000 call
| Previous close | 1.1200 |
| Open | 1.1200 |
| Bid | 0.5000 |
| Ask | 3.1000 |
| Strike | 18.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.1200 - 1.1200 |
| Contract range | N/A |
| Volume | |
| Open interest | 436 |
Business WireMelt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn., June 06, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.’s proprietary fast‑dissolving Zy
Business WireHarrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
NASHVILLE, Tenn., June 05, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study, re
Business WireHarrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn., May 15, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:
